
CNTB Stock Forecast & Price Target
CNTB Analyst Ratings
Bulls say
Connect Biopharma Hldgs is a strong investment due to the promising results of rademikibart in respiratory diseases, potential for expansion into chronic maintenance, and lower pricing compared to the industry average. However, the success of the company will heavily rely on the results of their upcoming clinical trials and securing sufficient funding. The company may also benefit from the FDA's flexibility in approving respiratory disease treatments and could attract more investors if their Phase 3 SEABREEZE trial is successful.
Bears say
Connect Biopharma Hldgs is developing rademikibart, a next-generation antibody for asthma and COPD with a unique mechanism of action that targets interleukin-4-receptor alpha. Despite promising preclinical data and a differentiated profile compared to existing treatments, the company's stock faces significant challenges. These include a lack of clinical data, potential dilution from future financings, and dependence on partner Simcere for success in the Chinese market. Additionally, the company's rapid onset mechanism may not be enough to differentiate the drug in the crowded respiratory market.
This aggregate rating is based on analysts' research of Connect Biopharma Holdings and is not a guaranteed prediction by Public.com or investment advice.
CNTB Analyst Forecast & Price Prediction
Start investing in CNTB
Order type
Buy in
Order amount
Est. shares
0 shares